← All trials
NCT01492556
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2011
- Primary completion
- Jun 1, 2014
- Completion date
- Jun 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Harbin Medical UniversityCollaborator
- Xinjiang Medical UniversityCollaborator
- Henan Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Guangxi Medical UniversityCollaborator
- Shanghai University of Traditional Chinese MedicineCollaborator
- Jiao Tong UniversityCollaborator
- Tsinghua UniversityCollaborator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
- Peking UniversityCollaborator
- China Ministry of HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.